Central retinal artery occlusion after catheter ablation of atrial fibrillation

Yasuhiro Matsuda | Masaharu Masuda | Mitsutoshi Asai | Osamu Iida | Takashi Kanda | Toshiaki Mano

Kansai Rosai Hospital Cardiovascular Center, Amagasaki, Japan

Correspondence
Masaharu Masuda, Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki-shi, Hyogo, 660-8511, Japan. Email: masuda-masaharu@kansaih.johas.go.jp

Abstract
Central retinal artery occlusion (CRAO) is a rare but severe and urgent complication of atrial fibrillation ablation. Awareness of this ophthalmologic complication and prompt treatment are needed because ischemic damage to the retina is irreversible from 4 hours after the onset of CRAO.

KEYWORDS
atrial fibrillation, cardiogenic embolism, catheter ablation, central retinal artery occlusion, complication

1 | INTRODUCTION

We report the first case with central retinal artery occlusion (CRAO), which is a rare but ophthalmic emergency complication, in periprocedural periods of atrial fibrillation ablation. In this case, sudden visual loss occurred after the procedure and visual loss was persisted. Operators should know the incidence and management of CRAO.

Catheter ablation is an important therapy for atrial fibrillation (AF). Although there is abundant evidence that catheter ablation is superior to antiarrhythmic drugs, there is a small but definite probability of complications in the periprocedural period. Two of the major complications of AF ablation are stroke and other thromboembolic events. Previous studies have reported incidences of thromboembolism associated with AF ablation of 0%-7%.2

Central retinal artery occlusion (CRAO) is an ophthalmic emergency because it causes sudden and severe visual loss.3 Prompt treatment is needed because ischemic damage to the retina is irreversible from 4 hours of onset.3

Embolism is the main cause of CRAO, and the main sources of embolism are the carotid artery and the heart.4 AF is known as a risk factor for retinal vessel occlusion, and some previous studies have reported on catheterization procedures as the cause of CRAO.6,7 However, no case reports are available on CRAO related to AF ablation.

We report a case of CRAO in the postprocedural period of AF ablation.

2 | CASE REPORT

A 79-year-old male patient was referred to our hospital because of dyspnea on exertion in May 2019. His CHA2DS2-VASc score was 3 points, and he had moderate aortic valve stenosis. AF was found on 12-lead electrocardiography. We performed a radiofrequency catheter ablation with pulmonary vein isolation and cavo-tricuspid isthmus ablation in May 2019. AF recurred at 4 months postablation.

After confirming there was no thrombus in the left atrial appendage by transesophageal echocardiography, we performed a second AF ablation in November 2019.

The patient had been taking apixaban 5 mg twice daily before the procedure. On the day of the procedure, the morning dose was withheld and the evening dose was administered.
The procedure was performed under intravenous conscious sedation with dexmedetomidine and fentanyl. Electrophysiological studies and catheter ablation were performed using an electrophysiological mapping catheter (Rhythmia™, Boston Scientific) and an open-irrigated linear ablation catheter with a 3.5-mm tip (INTELLATIP MiFi™, Boston Scientific).

The cardiac rhythm at the beginning of the procedure was atrial tachycardia, and electrophysiological study revealed that the atrial tachycardia was perimitral flutter. Ablation creating left atrial anterior line changed perimitral flutter into biatrial tachycardia. After that, lateral mitral isthmus linear ablation including both endocardial and epicardial radiofrequency application terminated the biatrial tachycardia.

After linear ablation of the left atrium, no atrial tachyarrhythmia was induced by atrial burst stimuli. Reconnections of the pulmonary vein and cavo-tricuspid isthmus were not found. In this case, the body mass index was high and glossoptosis with conscious sedation tended to occur irrespective of using noninvasive positive pressure ventilation. The procedural time was 209 minutes. We used heparin and set target activated clotting time at 300 seconds during the procedure (Figure 1). Baseline and procedural characteristics of the patient are shown in Table 1.

The patient was asymptomatic until visual loss in the left eye occurred 3.5 hours after the procedure. Eyesight in the left lower quadrant was limited to counting fingers, and eyesight in the rest of the left eye was light perception only. There was no identifiable ischemic stroke or hemorrhage which caused visual loss on brain computerized tomography or magnetic resonance imaging. We consulted with ophthalmology. A fundus examination revealed a cherry-red spot in the left eye and he was diagnosed with CRAO (Figure 2).

Ocular massage was performed, and nitroglycerine and 5000 units of heparin sodium were infused. However, eyesight did not improve. An infusion of 10 µg/hours of alprostadil was also initiated 4 hours after the symptoms onset and continued for 3 days. Carotid artery ultrasound performed on the day after the procedure showed no mobile plaque. Although peripheral vision was improved, central visual field loss of the left eye persisted. Because the patient needed physical therapy, he was discharged 8 days after the procedure.

3 | DISCUSSION
We report a case of CRAO occurring after AF ablation. In this case, sudden visual loss in the left eye occurred and did not improve well with treatment.

Central retinal artery occlusion can be caused by retinal artery embolism or hemodynamically induced retinal ischemia. The risk factors for CRAO are shown in Table 2.3-5 AF was a cause of CRAO. A previous study using implantable loop recorders reported that 15% of CRAO patients had subclinical AF.8

There have been few reports of ophthalmic complications of AF ablation. Although a previous study showed one patient developed a unilateral quadrantanopsia consistent with a retinal artery embolus after catheter ablation,9 there have been no reports about CRAO with complete unilateral visual loss. To our knowledge, this is the first case report to describe CRAO following AF ablation.

Ischemic damage to the retina is irreversible within 4 hours of the onset of CRAO3; therefore, prompt management is important. Common treatments for CRAO are shown in Table 3.3,10-18 Ocular massage was performed because the embolus in the central retinal artery was expected to be dislodged.3 As medical therapies, vasodilators such as nitroglycerine and anticoagulant such as heparin have been used; however, there is no evidence that these agents are effective.

**FIGURE 1** Activated clotting time and heparin dose during the procedure. We used heparin and set a target activated clotting time of 300 seconds during the procedure. Heparin was reversed with protamine at the end of the procedure.
FIGURE 2  The schema of fundus examination. A cherry-red spot, which is typically observed in CRAO, was found in fundus examination. CRAO, Central retinal artery occlusion

TABLE 1  Baseline and procedural characteristics of the patient

| Age | Gender | Type of arrhythmia | Past history | BMI (kg/m²) | LVEF (%) | LAD (mm) | Valvular heart disease | Preprocedural time (min) | Procedure |
|-----|--------|-------------------|--------------|-------------|-----------|----------|------------------------|-------------------------|-----------|
| 79  | Male   | AT                | HT           | 31          | 68        | 53       | Aortic valve stenosis  | 209                     | Anterior line and lateral mitral isthmus linear ablation |

Abbreviations: AT, Atrial tachycardia; BMI, body mass index; eGFR, Estimated glomerular filtration rate; HT, Hypertension; LAD, Left atrial diameter; LVEF, Left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

TABLE 2  Risk factors for central retinal artery occlusion

- Cardiovascular disease
- Atrial fibrillation
- Ischemic heart disease
- Hypertension
- Cerebrovascular disease
- Carotid artery stenosis
- Stroke/Transient ischemic attack
- Metabolic disease
- Dyslipidemia
- Diabetes mellitus
- Renal disease
- Nephrotic syndrome
- Hemodialysis
- Hematologic disease
- Leukemia
- Lymphoma
- Sickle cell anemia
- Others
- Fabry disease
- Marfan syndrome
- Incontinentia pigmènti
- Autoimmune disease
- Smoking
- Drug abuse
- Oral contraceptives
- Migraine
A recent study showed that digital subtraction angiography-guided superselective ophthalmic artery or selective carotid thrombolysis with urokinase and papaverine was an effective treatment method for CRAO.\(^{12}\)

Another study showed that alprostadil infusion resulted in significant visual improvement in patients with CRAO.\(^{11}\)

In this study, the logarithm of the minimum angle of resolution best-corrected visual acuity significantly improved from 2.73 to 1.48 at 1 month after the onset of CRAO, and all six patients experienced vision improvement.\(^{11}\) Our use of alprostadil for 3 days somewhat improved peripheral vision.

We needed a long procedural time in this case. Therefore, an embolic event was more likely to occur because long left atrium dwell time exposed this patient to thrombus formation on catheters.\(^{19}\) The differential diagnosis in this case is air embolism vs thromboembolism. In this case, the body mass index was high and glossoptosis with conscious sedation tended to occur irrespective of using noninvasive positive pressure ventilation. This condition induced a long apnea and might be a cause of an air embolism. Deep sedation with a laryngeal mask airway might be a preventive method. If possible, avoiding a long procedural time, which is a risk factor for complication,\(^{20}\) might also prevent complications.

To minimize the risk of permanent visual loss from CRAO, operators suspecting it should closely cooperate with an ophthalmologist to diagnose this disease as soon as possible.

---

**TABLE 3** Common treatments for central retinal artery occlusion

| Treatment                        | Goal of treatment                        | Effectiveness |
|----------------------------------|------------------------------------------|---------------|
| Ocular massage                   | Dislodgement of the embolus              | One case report reported vision improvement.\(^{10}\) |
| Paracentesis                     | Reduction in intraocular pressure         | No evidence of benefit |
| Acetazolamide                    | Reduction in intraocular pressure         | No evidence of benefit |
| Alprostadil                      | Improvement of blood flow                 | Vision improvement in all six patients\(^{11}\) |
| Nitrates                         | Improvement of blood flow                 | No evidence of benefit |
| Hyperbaric oxygen                | Improvement of blood oxygen               | No evidence of benefit |
| Inhalation of oxygen and carbon dioxide | Improvement of blood oxygen          | No evidence of benefit |
| Rebreathing of expired carbon dioxide | Improvement of blood oxygen          | No evidence of benefit |
| Heparin                          | Thrombolysis of the embolus              | No evidence of benefit |
| Thrombolysis                     | Thrombolysis of the embolus              | Effective with papaverine in 21/50 (42%) of patients\(^{12}\) |
| Retrograde injection of papaverine | Prevention of vasospasm                  | Effective with urokinase in 21/50 (42%) of patients\(^{12}\) |
| Pentoxifylline                   | Reduction in red blood cell rigidity      | No evidence of benefit |
| Steroids                         | Reduction in retinal edema               | No evidence of benefit |
| Laser arteriotomy and embolectomy | Lysis or dislodgement of the embolus     | Two case reports reported vision improvement.\(^{13}\) |

---

**CONCLUSIONS**

We present a case of CRAO, a rare, severe, and emergent complication that occurred after an AF ablative procedure. The cause may have been thromboembolism or an air embolism.

**ACKNOWLEDGMENTS**

We thank Libby Cone, MD, MA, and Guy Harris DO from DMC Corp. (http://www.dmed.co.jp/) for editing drafts of this manuscript.

**CONFLICT OF INTEREST**

None declared.

**AUTHOR CONTRIBUTIONS**

YM: involved in acquisition of data, drafting the manuscript, and revising the manuscript. MM: involved in drafting and revising the manuscript. OI, MA, TK, and TM: involved in revising the manuscript.

**ETHICAL APPROVAL**

This study complied with the Declaration of Helsinki. Written informed consent for catheter ablation and the use of data in this study was obtained from the patient, and the protocol was approved by our institutional review board (Reference number 2002004).
DATA AVAILABILITY STATEMENT
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study.

ORCID
Masaharu Masuda https://orcid.org/0000-0002-5566-466X

REFERENCES
1. Haegeli LM, Calkins H. Catheter ablation of atrial fibrillation: an update. *Eur Heart J*. 2014;35:2454-2459.
2. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace*. 2017;20:821-822.
3. Hayreh SS. Central retinal artery occlusion. *Indian J Ophthalmol*. 2018;66:1684-1694.
4. Hayreh SS, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. *Ophthalmology*. 2009;116:1928-1936.
5. Kewcharoen J, Tom ES, Wiboonchutikula C, et al. Prevalence of atrial fibrillation in patients with retinal vessel occlusion and its association: a systematic review and meta-analysis. *Curr Eye Res*. 2019;44:1337-1344.
6. Selton J, Cho YD, Han MH. Intra-arterial thrombolysis of central retinal artery occlusion following percutaneous atrial septal defect closure. *Catheter Cardiovasc Interv*. 2016;88:157-160.
7. Watson RA, Wellsing J, Hingorani R, et al. Atrial fibrillation post central retinal artery occlusion: role of implantable loop recorders. *Pacing Clin Electrophysiol*. 2020;43(9):992-999. https://doi.org/10.1111/pace.13990
8. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. *Circulation*. 2002;105:1077-1081.
9. Schmidt D. Ocular massage in a case of central retinal artery occlusion the successful treatment of a hitherto undescribed type of embolism. *Eur J Med Res*. 2000;5:157-164.
10. Malbin B, Padidam S, Burke M, et al. Intravenous prostaglandin E1 infusion for acute central retinal artery occlusion. *Ophthalmic Surg Lasers Imaging Retina*. 2019;50:55-58.
11. Wang R, Qian L, Wang Y, et al. Evaluation of ophthalmic artery branch retrograde intervention in the treatment of central retinal artery occlusion (CRAO). *Med Sci Monit*. 2017;23:114-120.
12. Cugati S, Varma DD, Chen CS, Lee AW. Treatment options for central retinal artery occlusion. *Curr Treat Options Neurol*. 2013;15:63-77.
13. Wang YL, Hui YN, Chen R, Jin YY, Tao J, Zhou YM. Central retinal artery occlusion after endovascular coil embolization for internal carotid artery aneurysm. *Int J Ophthalmol*. 2019;12:520-522.
14. Bioussé V, Calvetti O, Bruce BB, Newman NJ. Thrombolysis for central retinal artery occlusion. *J Neuroophthalmol*. 2007;27:215-230.
15. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. *Vision Res*. 1997;37:3483-3493.
16. Naniwadekar A, Joshi K, Greenspan A, Mainigi S. Use of the new contact force sensing ablation catheter dramatically reduces fluoroscopy time during atrial fibrillation ablation procedures. *Indian Pacing Electrophysiol J*. 2016;16:83-87.
17. Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. *Circ Arrhythm Electrophysiol*. 2013;6:1082-1088.

How to cite this article: Matsuda Y, Masuda M, Asai M, Iida O, Kanda T, Mano T. Central retinal artery occlusion after catheter ablation of atrial fibrillation. *Clin Case Rep*. 2021;9:e04255. https://doi.org/10.1002/ccr3.4255